The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Prediction of the SARS-CoV-2 (2019-nCoV) 3C-like protease (3CLpro) structure: virtual screening reveals velpatasvir, ledipasvir, and other drug repurposing candidates
Open accessAbstract
We prepared the three-dimensional model of the SARS-CoV-2 (aka 2019-nCoV) 3C-like protease (3CL pro) using the crystal structure of the highly similar (96% identity) ortholog from the SARS-CoV. All residues involved in the catalysis, substrate binding and dimerisation are 100% conserved. Comparison of the polyprotein PP1AB sequences showed 86% identity. The 3C-like cleavage sites on the coronaviral polyproteins are highly conserved. Based on the near-identical substrate specificities and high sequence identities, we are of the opinion that some of the previous progress of specific inhibitors development for the SARS-CoV enzyme can be conferred on its SARS-CoV-2 counterpart. With the 3CL pro molecular model, we performed virtual screening for purchasable drugs and proposed 16 candidates for consideration. Among these, the antivirals ledipasvir or velpatasvir are particularly attractive as therapeutics to combat the new coronavirus with minimal side effects, commonly fatigue and headache. The drugs Epclusa (velpatasvir/sofosbuvir) and Harvoni (ledipasvir/sofosbuvir) could be very effective owing to their dual inhibitory actions on two viral enzymes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Trott, O., & Olson, A. J. (2010) · Journal of Computational Chemistry · doi:10.1002/jcc.21334 · Cited by 38,412
Chan, J. F.-W., Yuan, S., Kok, K.-H., To, K. K.-W., Chu, H., Yang, J., Xing, F., Liu, J., Yip, C. C.-Y., Poon, R. W.-S., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30154-9 · Cited by 8,944
First case of 2019 novel coronavirus in the United States
Holshue, M. L., DeBolt, C., Lindquist, S., Lofy, K. H., Wiesman, J., Bruce, H., Spitters, C., Ericson, K., Wilkerson, S., Tural, A., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2001191 · Cited by 6,030
A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19
Cao, B., Wang, Y., Wen, D., Liu, W., Wang, J., Fan, G., Ruan, L., Song, B., Cai, Y., Wei, M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2001282 · Cited by 5,187
Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors
Jin, Z., Du, X., Xu, Y., Deng, Y., Liu, M., Zhao, Y., Zhang, B., Li, X., Zhang, L., Peng, C., et al. (2020) · Nature · doi:10.1038/s41586-020-2223-y · Cited by 4,358
Zhang, L., Lin, D., Sun, X., Curth, U., Drosten, C., Sauerhering, L., Becker, S., Rox, K., & Hilgenfeld, R. (2020) · Science · doi:10.1126/science.abb3405 · Cited by 2,895
Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings
Chu, C. M. (2004) · Thorax · doi:10.1136/thorax.2003.012658 · Cited by 1,645
Improved prediction of protein side‐chain conformations with SCWRL4
Krivov, G. G., Shapovalov, M. V., & Dunbrack, R. L. (2009) · Proteins: Structure, Function, and Bioinformatics · doi:10.1002/prot.22488 · Cited by 1,301
SARS: systematic review of treatment effects
Stockman, L. J., Bellamy, R., & Garner, P. (2006) · PLoS Medicine · doi:10.1371/journal.pmed.0030343 · Cited by 1,217
The penultimate rotamer library
Lovell, S. C., Word, J. M., Richardson, J. S., & Richardson, D. C. (2000) · Proteins: Structure, Function, and Genetics · doi:10.1002/1097-0134(20000815)40:3<389::aid-prot50>3.0.co;2-2 · Cited by 1,036
Beck, B. R., Shin, B., Choi, Y., Park, S., & Kang, K. (2020) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2020.03.025 · Cited by 816
Pillaiyar, T., Manickam, M., Namasivayam, V., Hayashi, Y., & Jung, S.-H. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01461 · Cited by 775
Dyall, J., Coleman, C. M., Hart, B. J., Venkataraman, T., Holbrook, M. R., Kindrachuk, J., Johnson, R. F., Olinger, G. G., Jahrling, P. B., Laidlaw, M., et al. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.03036-14 · Cited by 660
Lin, C.-W., Tsai, F.-J., Tsai, C.-H., Lai, C.-C., Wan, L., Ho, T.-Y., Hsieh, C.-C., & Chao, P.-D. L. (2005) · Antiviral Research · doi:10.1016/j.antiviral.2005.07.002 · Cited by 545
Small molecules targeting severe acute respiratory syndrome human coronavirus
Wu, C.-Y., Jan, J.-T., Ma, S.-H., Kuo, C.-J., Juan, H.-F., Cheng, Y.-S. E., Hsu, H.-H., Huang, H.-C., Wu, D., Brik, A., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0403596101 · Cited by 521
Potential inhibitors against 2019-nCoV coronavirus M protease from clinically approved medicines
Liu, X., & Wang, X.-J. (2020) · Journal of Genetics and Genomics · doi:10.1016/j.jgg.2020.02.001 · Cited by 464
Xu, Z., Shi, D., Han, J.-B., Ling, Y., Jiang, X., Lu, X., Li, C., Gong, L., Ge, G., Zhang, Y., et al. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01429-0 · Cited by 301
MTiOpenScreen: a web server for structure-based virtual screening
Labbé, C. M., Rey, J., Lagorce, D., Vavruša, M., Becot, J., Sperandio, O., Villoutreix, B. O., Tufféry, P., & Miteva, M. A. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv306 · Cited by 292
SARS-CoV 3CL protease cleaves its C-terminal autoprocessing site by novel subsite cooperativity
Muramatsu, T., Takemoto, C., Kim, Y.-T., Wang, H., Nishii, W., Terada, T., Shirouzu, M., & Yokoyama, S. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1601327113 · Cited by 274
Mechanism of the Maturation Process of SARS-CoV 3CL Protease
Hsu, M.-F., Kuo, C.-J., Chang, K.-T., Chang, H.-C., Chou, C.-C., Ko, T.-P., Shr, H.-L., Chang, G.-G., Wang, A. H.-J., & Liang, P.-H. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m502577200 · Cited by 262
3C-like Proteinase from SARS Coronavirus Catalyzes Substrate Hydrolysis by a General Base Mechanism
Huang, C., Wei, P., Fan, K., Liu, Y., & Lai, L. (2004) · Biochemistry · doi:10.1021/bi036022q · Cited by 215
Molecular dynamic simulations analysis of ritronavir and lopinavir as SARS-CoV 3CLpro inhibitors
Nukoolkarn, V., Lee, V. S., Malaisree, M., Aruksakulwong, O., & Hannongbua, S. (2008) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2008.07.030 · Cited by 176
Mutation of Glu-166 Blocks the Substrate-Induced Dimerization of SARS Coronavirus Main Protease
Cheng, S., Chang, G., & Chou, C. (2010) · Biophysical Journal · doi:10.1016/j.bpj.2009.12.4272 · Cited by 150
Therapeutic Drugs Targeting 2019-nCoV Main Protease by High-Throughput ScreeningPreprint
Li, Y., Zhang, J., Wang, N., Li, H., Shi, Y., Guo, G., Liu, K., Zeng, H., & Zou, Q. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.01.28.922922 · Cited by 128
Hu, T., Zhang, Y. L., Li, L., Wang, K., Chen, S., Chen, J., Ding, J., Jiang, H., & Shen, X. (2009) · Virology · doi:10.1016/j.virol.2009.03.034 · Cited by 108
Zhang, X. W., & Yap, Y. L. (2004) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2004.03.035 · Cited by 98
Long-Range Cooperative Interactions Modulate Dimerization in SARS 3CLpro
Barrila, J., Bacha, U., & Freire, E. (2006) · Biochemistry · doi:10.1021/bi0616302 · Cited by 85
Machine intelligence design of 2019-nCoV drugsPreprint
Gao, K., Nguyen, D. D., Wang, R., & Wei, G. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.01.30.927889 · Cited by 57
Kuo, C., & Liang, P. (2015) · ChemBioEng Reviews · doi:10.1002/cben.201400031 · Cited by 30
Homology Models of Wuhan Coronavirus 3CLpro ProteasePreprint
Stoermer, M. J. (2020) · ChemRxiv · doi:10.26434/chemrxiv.11637294.v1 · Cited by 12
Cited by
COVID-19: Transmission, prevention, and potential therapeutic opportunities
Lotfi, M., Hamblin, M. R., & Rezaei, N. (2020) · Clinica Chimica Acta · doi:10.1016/j.cca.2020.05.044 · Cited by 1,016
Drug repurposing approach to fight COVID-19
Singh, T. U., Parida, S., Lingaraju, M. C., Kesavan, M., Kumar, D., & Singh, R. K. (2020) · Pharmacological Reports · doi:10.1007/s43440-020-00155-6 · Cited by 480
Jothimani, D., Venugopal, R., Abedin, M. F., Kaliamoorthy, I., & Rela, M. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.06.006 · Cited by 469
Liu, H., Ye, F., Sun, Q., Liang, H., Li, C., Li, S., Lu, R., Huang, B., Tan, W., & Lai, L. (2021) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2021.1873977 · Cited by 334
Costanzo, M., De Giglio, M. A. R., & Roviello, G. N. (2020) · Current Medicinal Chemistry · doi:10.2174/0929867327666200416131117 · Cited by 296
Metadata
- Authors
- Chen, Y. W., Yiu, C.-P. B., & Wong, K.-Y.
- Venue
- F1000Research
- Publisher
- F1000 Research Ltd
- Published
- 2020-04-09
- Volume
- 9
- Pages
- 129
- ISSN
- 2046-1402 (ISSN-L)
- OpenAlex
- W3007386177
- Cited by
- 426
- References
- 30
- FWCI
- 12.01
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.